Abstract
Recent studies have established that the regulation of microRNAs (miRs) is a feature of the hypoxic response. In this review, we discuss the role of hypoxia-regulated miRs, with an emphasis on miR-210 and miR-373, and anticipate directions for clinical applications. The induction of miR-210 and miR-373 is dependent upon hypoxia inducible factor (HIF), and their up-regulation has been detected in a variety of solid tumors. Both miRs have been associated with adverse prognosis and metastatic potential. The increased expression of miR-210 is linked to an in vivo hypoxic signature. MiR- 210 also participates in endothelial and neuronal cells response to oxygen deprivation and may possess a role in the regulation of angiogenesis. A variety of miR-210 and miR-373 targets that may be relevant to hypoxia have been validated or proposed. Very recently, targets of these miRs that are implicated in DNA repair have been identified, thus establishing an additional link between the hypoxic tumor microenvironment and DNA damage. Extending beyond cancer biology, some of miR-210 targets are likely involved in the regulation of angiogenesis, and neuronal cell survival. Inactivation of miRs affected by hypoxia presents a promising therapeutic strategy in the case of difficult-to-treat cancers, as well as in other non-cancer-related diseases.
Keywords: Hypoxia, microRNA, cancer, ischemia, miR-210, miR-373, DNA repair
Current Pharmaceutical Design
Title: Emerging Roles of microRNAs in the Molecular Responses to Hypoxia
Volume: 15 Issue: 33
Author(s): Meredith E. Crosby, Cecilia M. Devlin, Peter M. Glazer, George A. Calin and Mircea Ivan
Affiliation:
Keywords: Hypoxia, microRNA, cancer, ischemia, miR-210, miR-373, DNA repair
Abstract: Recent studies have established that the regulation of microRNAs (miRs) is a feature of the hypoxic response. In this review, we discuss the role of hypoxia-regulated miRs, with an emphasis on miR-210 and miR-373, and anticipate directions for clinical applications. The induction of miR-210 and miR-373 is dependent upon hypoxia inducible factor (HIF), and their up-regulation has been detected in a variety of solid tumors. Both miRs have been associated with adverse prognosis and metastatic potential. The increased expression of miR-210 is linked to an in vivo hypoxic signature. MiR- 210 also participates in endothelial and neuronal cells response to oxygen deprivation and may possess a role in the regulation of angiogenesis. A variety of miR-210 and miR-373 targets that may be relevant to hypoxia have been validated or proposed. Very recently, targets of these miRs that are implicated in DNA repair have been identified, thus establishing an additional link between the hypoxic tumor microenvironment and DNA damage. Extending beyond cancer biology, some of miR-210 targets are likely involved in the regulation of angiogenesis, and neuronal cell survival. Inactivation of miRs affected by hypoxia presents a promising therapeutic strategy in the case of difficult-to-treat cancers, as well as in other non-cancer-related diseases.
Export Options
About this article
Cite this article as:
Crosby E. Meredith, Devlin M. Cecilia, Glazer M. Peter, Calin A. George and Ivan Mircea, Emerging Roles of microRNAs in the Molecular Responses to Hypoxia, Current Pharmaceutical Design 2009; 15 (33) . https://dx.doi.org/10.2174/138161209789649367
DOI https://dx.doi.org/10.2174/138161209789649367 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Transporter-Based Delivery of Anticancer Drugs to the Brain: Improving Brain Penetration by Minimizing Drug Efflux at the Blood-Brain Barrier
Current Pharmaceutical Design Microemulsions for Colorectal Cancer Treatments. General Considerations and Formulation of Methotrexate
Mini-Reviews in Medicinal Chemistry Stimuli-Responsive Nanoparticles for siRNA Delivery
Current Pharmaceutical Design Astrocyte Signaling and Multiple Sclerosis
Current Signal Transduction Therapy Regional Differences in Adaptation of CNS Mu Opioid Receptors to Chronic Opioid Agonist Administration
Current Neuropharmacology Novel Agents Targeting Bioactive Sphingolipids for the Treatment of Cancer
Current Medicinal Chemistry Overcoming the Blood-Brain Barrier for Chemotherapy: Limitations, Challenges and Rising Problems
Anti-Cancer Agents in Medicinal Chemistry Diffuse Intrinsic Pontine Glioma: New Pathophysiological Insights and Emerging Therapeutic Targets
Current Neuropharmacology Adhesion Dependent Signalling in the Tumour Microenvironment: The Future of Drug Targetting
Current Pharmaceutical Design Radiolabeled Glucose Derivatives for Tumor Imaging Using SPECT and PET
Current Medicinal Chemistry State of the Art Molecular Pharmacology, Pathogenesis and Epigenetics of 3 Major Cancers: Lung Cancer, Ovarian Cancer, and Gliomas
Current Molecular Pharmacology Approaching Neurological Diseases to Reduce Mobility Limitations in Older Persons
Current Pharmaceutical Design Overcoming the Drug Resistance Problem with Second-Generation Tyrosine Kinase Inhibitors: From Enzymology to Structural Models
Current Medicinal Chemistry Investigation of in Vitro Release Dynamics of Cisplatin from Genipin Crosslinked Gelatin Nanocarriers
Drug Delivery Letters Matrix Metalloproteinase Inhibitor MMI-166 Suppresses the Growth of SW1990 Human Pancreatic Cancer Cells
Current Signal Transduction Therapy Peptide modules for overcoming barriers of nucleic acids transport to cells
Current Topics in Medicinal Chemistry Highly Organized Nanostructures for Brain Drug Delivery - New Hope or Just a Fad?
CNS & Neurological Disorders - Drug Targets Radiopharmaceuticals for Oncology Drug Development: A Pharmaceutical Industry Perspective
Current Pharmaceutical Design Sulfur Containing Acridine Derivatives in Preclinical Studies with Cancer Cell Lines
Current Medicinal Chemistry Sphingosine Kinases Signalling in Carcinogenesis
Mini-Reviews in Medicinal Chemistry